Specifically, it has been shown that palbociclib administration increases glucose utilization in cancer, whereas cyclin D3-CDK6 can directly phosphorylate and inhibit the activity of two key enzymes in the glycolytic pathway [23,24]. Here, CDK6 is linked to cancer.